Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMD NASDAQ:GHRS NASDAQ:IMNM NASDAQ:KOD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$12.79-1.8%$12.23$5.60▼$17.43$954.77M1.762.21 million shs3.31 million shsGHRSGH Research$12.89-3.9%$14.22$6.00▼$20.50$670.67M0.97326,199 shs240,812 shsIMNMImmunome$9.00-2.3%$9.90$5.15▼$16.73$783.41M1.92994,830 shs800,424 shsKODKodiak Sciences$9.73-3.3%$7.53$1.92▼$11.60$513.96M2.44451,513 shs303,438 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix+2.20%-11.00%+26.14%-10.69%+132.68%GHRSGH Research-0.67%-3.66%+8.14%-2.68%+57.88%IMNMImmunome-2.02%-0.75%-4.95%-2.95%-37.00%KODKodiak Sciences+2.76%+16.71%+27.34%+149.63%+322.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$12.79-1.8%$12.23$5.60▼$17.43$954.77M1.762.21 million shs3.31 million shsGHRSGH Research$12.89-3.9%$14.22$6.00▼$20.50$670.67M0.97326,199 shs240,812 shsIMNMImmunome$9.00-2.3%$9.90$5.15▼$16.73$783.41M1.92994,830 shs800,424 shsKODKodiak Sciences$9.73-3.3%$7.53$1.92▼$11.60$513.96M2.44451,513 shs303,438 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix+2.20%-11.00%+26.14%-10.69%+132.68%GHRSGH Research-0.67%-3.66%+8.14%-2.68%+57.88%IMNMImmunome-2.02%-0.75%-4.95%-2.95%-37.00%KODKodiak Sciences+2.76%+16.71%+27.34%+149.63%+322.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 2.88Moderate Buy$18.0040.85% UpsideGHRSGH Research 2.88Moderate Buy$32.00148.25% UpsideIMNMImmunome 3.00Buy$22.89154.32% UpsideKODKodiak Sciences 2.00Hold$11.7520.76% UpsideCurrent Analyst Ratings BreakdownLatest KOD, GHRS, CRMD, and IMNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025CRMDCorMedixJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$22.009/5/2025IMNMImmunomeCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$26.008/25/2025IMNMImmunomeGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/22/2025IMNMImmunomeEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$18.008/18/2025KODKodiak SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$3.00 ➝ $5.008/14/2025KODKodiak SciencesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderweight$4.00 ➝ $7.008/14/2025KODKodiak SciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$15.008/13/2025GHRSGH ResearchZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/8/2025CRMDCorMedixHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $17.008/7/2025IMNMImmunomeJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$23.00 ➝ $22.008/7/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$21.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$43.47M21.95N/AN/A$1.40 per share9.13GHRSGH ResearchN/AN/AN/AN/A$3.44 per shareN/AIMNMImmunome$12.59M62.23N/AN/A$2.27 per share3.96KODKodiak SciencesN/AN/AN/AN/A$2.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix-$17.93M$0.7517.0413.60N/A42.11%42.73%34.19%10/29/2025 (Estimated)GHRSGH Research-$38.96M-$0.74N/AN/AN/AN/A-16.71%-16.06%11/13/2025 (Estimated)IMNMImmunome-$292.96M-$3.08N/AN/AN/A-1,687.08%-76.10%-65.14%11/12/2025 (Estimated)KODKodiak Sciences-$176.21M-$3.80N/AN/AN/AN/A-155.27%-63.29%11/13/2025 (Estimated)Latest KOD, GHRS, CRMD, and IMNM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025KODKodiak Sciences-$1.01-$1.03-$0.02-$1.03N/AN/A8/7/2025Q2 2025CRMDCorMedix$0.20$0.28+$0.08$0.28$29.88 million$39.74 million8/7/2025Q2 2025GHRSGH Research-$0.22-$0.15+$0.07-$0.15N/AN/A8/6/2025Q2 2025IMNMImmunome-$0.52-$0.50+$0.02-$0.50$1.03 million$4.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedixN/A7.827.52GHRSGH ResearchN/A29.4929.49IMNMImmunomeN/A12.1312.13KODKodiak SciencesN/A3.483.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%GHRSGH Research56.90%IMNMImmunome44.58%KODKodiak Sciences89.06%Insider OwnershipCompanyInsider OwnershipCRMDCorMedix5.30%GHRSGH ResearchN/AIMNMImmunome7.69%KODKodiak Sciences45.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3074.65 million70.69 millionOptionableGHRSGH Research1052.03 millionN/AOptionableIMNMImmunome4087.05 million80.35 millionOptionableKODKodiak Sciences9052.82 million28.58 millionOptionableKOD, GHRS, CRMD, and IMNM HeadlinesRecent News About These CompaniesAdage Capital Partners GP L.L.C. Buys 186,180 Shares of Kodiak Sciences Inc. $KODSeptember 9 at 4:41 AM | marketbeat.comKodiak Sciences Inc. $KOD Shares Sold by Invesco Ltd.September 9 at 3:08 AM | marketbeat.comBrokers Offer Predictions for Kodiak Sciences Q3 EarningsSeptember 7 at 6:50 AM | marketbeat.comNuveen LLC Buys New Shares in Kodiak Sciences Inc. $KODSeptember 7 at 3:14 AM | marketbeat.comAnalysts Set Expectations for Kodiak Sciences Q3 EarningsSeptember 7 at 2:29 AM | americanbankingnews.comKodiak Sciences Inc. $KOD Shares Purchased by Nantahala Capital Management LLCSeptember 3, 2025 | marketbeat.comKodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)September 2, 2025 | prnewswire.comJim Cramer on Kodiak Sciences: “That’s a Pure Spec Stock”August 29, 2025 | insidermonkey.comHarbour BioMed Reports 2025 Interim ResultsAugust 27, 2025 | prnewswire.comCramer's Lightning Round: Oklo is a buyAugust 27, 2025 | msn.comICONIQ Capital LLC Purchases 249,699 Shares of Kodiak Sciences Inc. $KODAugust 26, 2025 | marketbeat.comKodiak Sciences: Odds May Be Narrowing For Longer Lasting Eye Disease Med ApprovalAugust 22, 2025 | seekingalpha.comQ3 EPS Estimates for Kodiak Sciences Raised by HC WainwrightAugust 22, 2025 | marketbeat.comKodiak Sciences Inc.'s (NASDAQ:KOD) high institutional ownership speaks for itself as stock continues to impress, up 11% over last weekAugust 20, 2025 | finance.yahoo.comKodiak Sciences (NASDAQ:KOD) Trading Down 6% - Here's What HappenedAugust 20, 2025 | marketbeat.comHC Wainwright Boosts Kodiak Sciences (NASDAQ:KOD) Price Target to $5.00August 20, 2025 | marketbeat.comKodiak Sciences to Present at American Chemical Society Fall 2025August 19, 2025 | prnewswire.comKodiak Sciences (NASDAQ:KOD) Shares Up 8.4% - Here's WhyAugust 17, 2025 | marketbeat.comKodiak Sciences (NASDAQ:KOD) Shares Gap Up - Time to Buy?August 16, 2025 | marketbeat.comKodiak Sciences (NASDAQ:KOD) Rating Increased to Neutral at JPMorgan Chase & Co.August 16, 2025 | marketbeat.comXTX Topco Ltd Acquires New Stake in Kodiak Sciences Inc. (NASDAQ:KOD)August 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKOD, GHRS, CRMD, and IMNM Company DescriptionsCorMedix NASDAQ:CRMD$12.79 -0.24 (-1.84%) Closing price 04:00 PM EasternExtended Trading$12.73 -0.06 (-0.46%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.GH Research NASDAQ:GHRS$12.89 -0.53 (-3.95%) Closing price 04:00 PM EasternExtended Trading$12.85 -0.04 (-0.31%) As of 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Immunome NASDAQ:IMNM$9.00 -0.21 (-2.28%) Closing price 04:00 PM EasternExtended Trading$9.16 +0.16 (+1.78%) As of 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Kodiak Sciences NASDAQ:KOD$9.73 -0.33 (-3.28%) Closing price 04:00 PM EasternExtended Trading$9.86 +0.13 (+1.28%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
